All-cause mortality, cardiovascular readmission for myocardial infarction, heart failure, and stroke risk higher for PCI versus CABG
TUESDAY, Jan. 6, 2026 (HealthDay News) — For women with severe coronary artery disease (CAD), percutaneous coronary intervention (PCI) is associated with increased risks for major adverse cardiovascular and cerebrovascular events (MACCE) and all-cause mortality compared with coronary artery bypass grafting (CABG), according to a study published online Nov. 25 in the European Heart Journal.
Kevin R. An, M.D., M.P.H., from Sunnybrook Health Sciences Centre at the University of Toronto, and colleagues compared long-term outcomes of PCI and CABG in women with chronic severe CAD in a propensity score-matched retrospective cohort study. A total of 2,469 women underwent PCI and 3,721 underwent CABG; 2,033 pairs were identified after propensity score matching.
The researchers found that MACCE was higher with PCI versus CABG at a median follow-up of 5.1 years (hazard ratio, 1.81). Compared with CABG, all-cause mortality was higher with PCI (hazard ratio, 1.34), as was cardiovascular readmission (myocardial infarction, heart failure, or stroke; hazard ratio, 1.40).
“For now, treatment decisions should remain individualized,” An said in a statement. “Although our study suggests that bypass surgery may offer more long-term protection compared to stents, anatomical considerations, individual surgical risk, and patient preferences remain critical.”
Abstract/Full Text (subscription or payment may be required)
Recommendations Updated for Adult Stroke Rehabilitation, Recovery
Dementia, Stroke Risk Elevated for Those With Severe Mental Illness
NOACs Linked to Slower Cognitive Decline in Patients With A-Fib, Alzheimer Disease
Intensive BP Lowering Reduces Recurrent Stroke After Intracerebral Hemorrhage
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians
Physical Activity Reduces Stroke, Mortality, Regardless of A-Fib
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines